.jpeg)
{{ variable.name }}
Tenofovir alafenamide fumarate tablets (Vemlidy) is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits viral replication by inhibiting the reverse transcriptase activity of hepatitis B virus (HBV) and blocking the extension of viral DNA chains.
Common name: Tenofovir alafenamide fumarate tablets
Trade name: VEMLIDY®
English name: T enofovirAlafenamide Tablets
It is used to treat chronic hepatitis B virus (HBV) infection in adults with well-compensated liver function (no decompensation of cirrhosis).
Specifications : Each tablet contains 25 mg tenofovir alafenamide (equivalent to 28 mg fumarate).
Characteristics : Yellow round film-coated tablet, engraved with "GSI" on one side and "25" on the other side.
Active ingredient :TenofovirAlafenamide.
Excipients : Croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose; coating contains iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide.
Regular dosage of : Once a day, 25mg (1 tablet) each time, to be taken with food.
Handling of missed doses : If you miss a dose, you should take it as soon as possible; if it is close to the next dose time, skip the missed dose and do not take double dose.
Vomiting treatment : If you vomit after taking the medicine, there is no need to take a supplement, and you can take the next medicine as originally planned.
Renal insufficiency :
Mild to moderate (eGFR≥15mL/min): no adjustment is required.
End-stage renal disease (eGFR<15mL/min) or dialysis patients: Not recommended.
Hepatic insufficiency :
Mild (Child-PughA): No adjustment required.
Moderate to severe (Child-PughB/C): Not recommended.
Dietary requirements : Must be taken with food to increase absorption rate.
Contraindications : There are no clear contraindications, but you need to be alert to HIV co-infection (combination with anti-HIV treatment is required).
Monitoring requirements : Renal function (serum creatinine, urine protein, etc.), HBV DNA load and liver function need to be monitored before and during medication.
U200c for pregnant women: The pros and cons need to be weighed, and medication use during pregnancy needs to be registered (antiretroviral pregnancy registration system).
U200c during lactation: Avoid breastfeeding (safety unknown).
Children : Safety for people under 18 years of age has not been established.
U200c for the elderly: No dose adjustment is required, but renal function needs to be closely monitored.
Common (≥5%): Headache, abdominal pain, fatigue, cough, nausea, back pain.
Severe :
Lactic acidosis/hepatic steatosis (rare but fatal).
HBV worsens acutely after discontinuation of medication.
Renal function impairment (such as Fanconi syndrome).
P-gp/BCRP inducer (such as rifampicin, St. John's wort): May reduce drug efficacy, avoid combined use.
Nephrotoxic drugs (such as NSAIDs, aminoglycosides): Increase the risk of kidney damage and require monitoring.
Drugs without significant interaction : Sofosbuvir/velpatasvir, ethinyl estradiol, etc.
Store below 30°C (86°F), keep the original packaging sealed and moisture-proof.